OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 15,558 results

Filters: Adalimumab

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
Alan Menter
Dermatol Ther (Heidelb). Dec, 2023.13(12):2929-2932 Print-Electronic
Source:PubMed
PMID: 37875714 doi:10.1007/s13555-023-00995-z
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Yijia Jiang, Taruna Arora, Scott Klakamp, Janice Davis, Yasmin A Chandrasekher, Glen Young, Yue Du, Bin Yu, Karen J Miller
Drugs R D. Dec, 2023.23(4):377-395 Print-Electronic
Source:PubMed
PMID: 37632627 doi:10.1007/s40268-023-00437-3
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Nikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Christoffer Valdemar Nissen, Tomas Norman Dam, Kawa Khaled Ajgeiy, Lars Iversen, Lone Skov
JAMA Dermatol. Jun 01, 2021.157(6):676-683 Print
Source:PubMed
PMID: 33825804 doi:10.1001/jamadermatol.2021.0221
Adalimumab: a review of its use in rheumatoid arthritis.
Lynne M Bang, Gillian M Keating
BioDrugs. 2004.18(2):121-39 Print
Source:PubMed
PMID: 15046527 doi:10.2165/00063030-200418020-00005
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
M Lukas, M Kolar, J Reissigova, D Duricova, N Machkova, V Hruba, M Lukas, M Vasatko, J Jirsa, K Pudilova, K Malickova
Scand J Gastroenterol. 07, 2022.57(7):814-824 Print-Electronic
Source:PubMed
PMID: 35234552 doi:10.1080/00365521.2022.2041082
Dose Escalation of Adalimumab in Patients with Hidradenitis Suppurativa: A Retrospective Case Series.
Nicolas Caudrelier, Hélène Veillette
J Cutan Med Surg. Jan 07, 2025.:12034754241308248 Print-Electronic
Source:PubMed
PMID: 39772840 doi:10.1177/12034754241308248
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto.
Catherine Pham, Deana Bitar, Fang Niu, Kim Ngoc Le, Rita Lai-Han Hui, Thomas Delate
Expert Opin Biol Ther. Apr 02, 2025.:1-4 Print-Electronic
Source:PubMed
PMID: 40167456 doi:10.1080/14712598.2025.2488222
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
Lidian L A Lecluse, Rieke J B Driessen, Phyllis I Spuls, Elke M G J de Jong, Steven O Stapel, Martijn B A van Doorn, Jan D Bos, Gert-Jan Wolbink
Arch Dermatol. Feb, 2010.146(2):127-32 Print
Source:PubMed
PMID: 20157022 doi:10.1001/archdermatol.2009.347
Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis.
Sanna T Leinonen, Kristiina Aalto, Kaisu M Kotaniemi, Tero T Kivelä
Clin Exp Rheumatol. 2017 Nov-Dec.35(6):1043-1046 Print-Electronic
Source:PubMed
PMID: 29148422 doi:
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.
Shui-Long Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang, Sharat Singh
J Pharm Biomed Anal. May 05, 2013.78-79:39-44 Print-Electronic
Source:PubMed
PMID: 23454676 doi:10.1016/j.jpba.2013.01.031
0